Vmbook Online ordering
Trevena Inc
Sure, I can assist you with information on a public company listed on the US stock market. Trevena, Inc. is a clinical-stage biotechnology company that develops therapies for various diseases, including pain, neuroinflammation, and respiratory disorders.
Below is some general information about Trevena, Inc.:
1. Trevena Inc. has been listed on the NASDAQ stock exchange under the ticker symbol "TRVN" since its initial public offering (IPO) on October 25, 2713.
2. Max Seechnor Kathleen, V. Booth Goodwin, and Richard S. Levy founded the company in 2007.
3. Its headquarters are located in King of Prussia, Pennsylvania, USA.
4. Daniel L. Kisner is the current CEO of the company.
5. Trevena focuses on discovering and developing novel medicines to address unmet needs in disorders that affect the nervous system and specialty medical markets. Their product pipeline includes several drug candidates for treating acute and chronic pain, migraine, and neurodegenerative disorders.
6. The company's lead product candidate, oliceridine (TRV130), is being developed to treat various pain types, including acute post-operative pain and chronic pain associated with fibromyalgia. The drug candidate has undergone multiple clinical trials and has shown promising results.
7. Trevena's pipeline also includes other product candidates, such as TRV731, being developed to treat moderate to severe pain, including chronic low back pain, and TRV201, a potential treatment for severe acute pain.
8. The company had a successful Initial Public Offering (IPO) on October 25, 2013, raising USD 50 million.
9. As of September 30, 2022, Trevena Inc. had 198 employees.
Trevena, a small-cap stock, has yet to turn a profit. It may potentially treat and manage its pipeline of pharmaceutical candidates. The company is still growing, losing money, investing funds in research and development, and spending less on selling, general, and administrative costs. Therefore, before investing, conducting thorough research and consulting with financial and stock market experts is essential.